Author

Brian P. Hanratty

Fred Hutch Cancer CenterORCID 0000-0003-4580-649XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Colm M. MorrisseyiD· 2 shared Peter S. NelsoniD· 2 shared Armand Bankhead· 1 shared Arthur J. Y. HuangiD· 1 shared Bruce MontgomeryiD· 1 shared Colin C. PritchardiD· 1 shared Dapei LiiD· 1 shared Divin Wilson· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Colm M. MorrisseyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer

Shan Li, Kai Song, Huiyun Sun, Yong Tao, Arthur J. Y. Huang, Vipul Bhatia, Brian P. Hanratty, Radhika A. Patel, Henry W. Long, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, Thomas G. Graeber, John K. Lee

This study reprograms AR-active prostate cancer to NEPC using ASCL1 and NeuroD1, revealing their role in silencing AR and altering chromatin structure.

bioRxiv · Feb 12, 2025 · PreprintCancer Biology

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

Sander B. Frank, Thomas W. Persse, I. M. Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau, Michael Yang, Brian P. Hanratty, Ruth F. Dumpit, Colm M. Morrissey, Eva Corey, , Peter S. Nelson

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

bioRxiv · Jul 16, 2024 · PreprintCancer Biology